Lushang Freda PharmaceuticalLtd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Lushang Freda PharmaceuticalLtd has a total shareholder equity of CN¥4.8B and total debt of CN¥457.4M, which brings its debt-to-equity ratio to 9.6%. Its total assets and total liabilities are CN¥6.1B and CN¥1.3B respectively. Lushang Freda PharmaceuticalLtd's EBIT is CN¥194.1M making its interest coverage ratio -2.2. It has cash and short-term investments of CN¥2.9B.
Anahtar bilgiler
9.6%
Borç/özkaynak oranı
CN¥457.35m
Borç
| Faiz karşılama oranı | -2.2x |
| Nakit | CN¥2.94b |
| Eşitlik | CN¥4.76b |
| Toplam yükümlülükler | CN¥1.34b |
| Toplam varlıklar | CN¥6.10b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares
Jun 21
Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?
Apr 16Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations
Mar 28Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Feb 27Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600223's short term assets (CN¥4.3B) exceed its short term liabilities (CN¥1.2B).
Uzun Vadeli Yükümlülükler: 600223's short term assets (CN¥4.3B) exceed its long term liabilities (CN¥106.7M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600223 has more cash than its total debt.
Borcun Azaltılması: 600223's debt to equity ratio has reduced from 331.6% to 9.6% over the past 5 years.
Borç Kapsamı: 600223's debt is well covered by operating cash flow (45.4%).
Faiz Kapsamı: 600223 earns more interest than it pays, so coverage of interest payments is not a concern.